Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRJ1-3024 in advanced solid tumors
NCT05159700Phase 1Active, not recruiting
- Sponsor
- Zhuhai Yufan Biotechnologies Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prj1-3024 in solid tumor (advanced stage), sponsored by Zhuhai Yufan Biotechnologies Co., Ltd. Primary endpoint: Dose-Limiting Toxicity at 21 days. Started Mar 2022; status: active, not recruiting.
02
Drugs
prj1-3024
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05159700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159700.